What was the impact of the PLAVIX® patent litigation on BMY's Q2 2007 results?

In Q2 2007, BMY reported a favorable court decision upholding the validity and enforceability of the PLAVIX® patent, enjoining Apotex from infringement. While Apotex has appealed this decision, the ruling allowed for a release of the $400 million bond previously posted as collateral. The estimated impact of the at-risk launch of generic clopidogrel bisulfate was approximately $50 million to $100 million for the quarter. Despite this, PLAVIX® sales increased 4% to $1.19 billion in Q2 2007.

How is generic competition affecting BMY's established products?

Generic competition continues to significantly impact some of BMY's older products. For instance, PRAVACHOL® sales decreased by 59% in Q2 2007 due to increased generic competition in the U.S. and Europe. TAXOL® sales also declined 36% due to generic entry in Europe and Japan. The company is actively managing these pressures through portfolio diversification and focusing on newer, growing products.

What are the key drivers of growth for Bristol-Myers Squibb?

BMY's growth is being driven by several key products. ABILIFY®, an antipsychotic, saw total revenue increase 27% in Q2 2007. The SUSTIVA® Franchise, used for HIV treatment, increased 21% in Q2. REYATAZ®, another HIV treatment, grew 8% in Q2. Newer products like BARACLUDE® and ORENCIA® also showed substantial growth, contributing to the company's overall performance.

What are the significant legal and regulatory matters facing the company?

BMY is involved in several significant legal and regulatory matters. These include ongoing patent litigation concerning PLAVIX®, with an appeal pending after a favorable ruling. The company has also reached an agreement in principle to settle investigations related to drug pricing, sales, and marketing activities for approximately $499 million. Additionally, investigations by the FTC and New York State Attorney General's Office regarding PLAVIX® settlement practices are ongoing. These matters pose potential financial and operational risks.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2007

Summary

Bristol-Myers Squibb Company (BMY) reported its second-quarter and first-half 2007 financial results, showing modest revenue growth driven by key products like PLAVIX®, ABILIFY®, and REYATAZ®, partially offset by generic competition for PRAVACHOL®. The company's net sales for the quarter increased by 1% to $4.9 billion, with net earnings rising by 6% to $706 million. For the first six months, net sales saw a slight decrease of 1% to $9.4 billion, while net earnings remained relatively flat at $1.4 billion. Significant legal developments, particularly concerning the PLAVIX® patent litigation with Apotex, concluded with a favorable court decision for BMY, though an appeal is pending. The company also addressed ongoing investigations and settlements related to pricing and marketing practices, including a proposed $499 million settlement for certain investigations. These legal matters and the impact of generic competition on key products present ongoing risks to future financial performance and liquidity.

Key Highlights

1Net sales for Q2 2007 increased 1% to $4.9 billion, while net earnings grew 6% to $706 million.
2For the first six months of 2007, net sales decreased 1% to $9.4 billion, with net earnings largely flat at $1.4 billion.
3The company's largest product, PLAVIX®, saw Q2 sales increase 4% to $1.19 billion, despite ongoing patent litigation and some impact from generic competition.
4Significant legal headwinds persist, including the ongoing PLAVIX® patent litigation appeal and investigations into pricing and marketing practices, with a proposed $499 million settlement for certain matters.
5Key growth drivers included ABILIFY® (up 27% in Q2), SUSTIVA® Franchise (up 21% in Q2), and REYATAZ® (up 8% in Q2), while PRAVACHOL® sales declined significantly due to generic competition.
6Research and development expenses increased by 5% in Q2 to $778 million, reflecting investments in late-stage compounds and upfront/milestone payments.
7The company's financial position remains strong with cash, cash equivalents, and marketable securities totaling $4.6 billion at June 30, 2007, and working capital of $4.9 billion.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2007

Summary

Key Highlights

Frequently Asked Questions